Table 2.
Clinical applications of highly expressed miR-146b in PTC.
| Mode of Implication | Specimens | Experiments | Reference |
|---|---|---|---|
| Predicts the poor prognosis | Thyroid cancer tissue | Quantitative polymerase chain reaction | [32] |
| Differentiates malignancy from benign lesions | Thyroid fine needle aspiration | Quantitative polymerase chain reaction | [43,44,45] |
| Distinguishes between benign and malignant | Plasma | Quantitative polymerase chain reaction | [47] |
| Acts as biomarkers for the PTC recurrence | Thyroid cancer tissue and plasma | Quantitative polymerase chain reaction | [48] |
| Distinguishes PTC from FTC and ATC | Thyroid cancer tissue | In Situ Hybridization Analysis | [49] |
| Characterizes classic PTC subtypes | Thyroid cancer tissue | Quantitative polymerase chain reaction | [26] |
| Predicts central neck lymph node metastasis preoperatively | Thyroid cancer tissue | Quantitative polymerase chain reaction | [50] |